Literature DB >> 11729028

Measuring P50 suppression and prepulse inhibition in a single recording session.

G A Light1, D L Braff.   

Abstract

OBJECTIVE: Two distinct measures have been used to assess inhibitory gating deficits in schizophrenia patients: P50 suppression and prepulse inhibition of the startle response. It remains unclear whether both measures can be assessed in a single testing session.
METHOD: Twelve normal subjects underwent testing in a carefully designed combined P50/prepulse inhibition session using stimulus characteristics similar to those described in the existing literature.
RESULTS: The levels of both P50 suppression and prepulse inhibition obtained in the combined session were highly similar to those obtained in independent testing of previous cohorts of normal subjects. As in previous experiments, P50 suppression and prepulse inhibition were not significantly correlated.
CONCLUSIONS: Measuring P50 suppression and prepulse inhibition in a single session is feasible and offers a unique opportunity to assess these two distinct gating measures contemporaneously in cohorts of normal comparison subjects and schizophrenia patients, so that temporal shifts in one or both measures are minimized.

Entities:  

Mesh:

Year:  2001        PMID: 11729028     DOI: 10.1176/appi.ajp.158.12.2066

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  13 in total

1.  Electroencephalography (EEG) and event-related potentials (ERPs) with human participants.

Authors:  Gregory A Light; Lisa E Williams; Falk Minow; Joyce Sprock; Anthony Rissling; Richard Sharp; Neal R Swerdlow; David L Braff
Journal:  Curr Protoc Neurosci       Date:  2010-07

2.  Much ado about (almost) nothing: response to 'prepulse lost and regained'.

Authors:  Neal R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2005-01-06       Impact factor: 4.530

3.  Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 4.  Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

5.  Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats.

Authors:  Neal R Swerdlow; Mark A Geyer; Jody M Shoemaker; Gregory A Light; David L Braff; Karen E Stevens; Richard Sharp; Michelle Breier; Alaina Neary; Pamela P Auerbach
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

6.  Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

Authors:  Philipp A Csomor; Katrin H Preller; Mark A Geyer; Erich Studerus; Theodor Huber; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2014-05-07       Impact factor: 7.853

7.  Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats.

Authors:  Michelle R Breier; Brittanni Lewis; Jody M Shoemaker; Gregory A Light; Neal R Swerdlow
Journal:  Behav Brain Res       Date:  2010-01-18       Impact factor: 3.332

8.  Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History.

Authors:  Tiffany A Greenwood; Gregory A Light; Neal R Swerdlow; Monica E Calkins; Michael F Green; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Robert Freedman; David L Braff
Journal:  Am J Psychiatry       Date:  2015-10-06       Impact factor: 18.112

9.  Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow; Anthony J Rissling; Allen Radant; Catherine A Sugar; Joyce Sprock; Marlena Pela; Mark A Geyer; David L Braff
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

10.  Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1).

Authors:  Larry J Seidman; Gerhard Hellemann; Keith H Nuechterlein; Tiffany A Greenwood; David L Braff; Kristin S Cadenhead; Monica E Calkins; Robert Freedman; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Ann Olincy; Allen D Radant; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Michael F Green
Journal:  Schizophr Res       Date:  2015-02-11       Impact factor: 4.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.